FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309182708> ?p ?o ?g. }

• W4309182708 endingPage "332" @default.
• W4309182708 startingPage "322" @default.
• W4309182708 abstract "Significance Statement The syndrome of inappropriate antidiuresis (SIAD) is a major cause of hypotonic hyponatremia. Despite its prevalence, treatment options are sparse, and data on their effect on hyponatremia-associated morbidity such as neurocognitive impairment are largely lacking. New treatment options are needed. The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin promotes osmotic diuresis via urinary glucose excretion and could be used as a treatment for chronic SIAD. This randomized, double-blind, placebo-controlled, crossover trial with 14 participants revealed that empagliflozin is well tolerated and effective compared with placebo. In addition, treatment with empagliflozin possibly led to an improvement in neurocognitive function. The results set the stage for further studies evaluating empagliflozin as a treatment option in patients with SIAD-induced hyponatremia. Background The syndrome of inappropriate antidiuresis (SIAD) is characterized by a reduction of free water excretion with consecutive hypotonic hyponatremia and is therefore challenging to treat. The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin promotes osmotic diuresis via urinary glucose excretion, likely leading to increased electrolyte free water clearance. Methods In this randomized, double-blind, placebo-controlled, crossover trial, we compared 4-week treatment with empagliflozin 25 mg/d to placebo in outpatients with chronic SIAD-induced hyponatremia. At baseline and after both treatment cycles, patients underwent different assessments including neurocognitive testing (Montreal Cognitive Assessment [MoCA]). The primary end point was the difference in serum sodium levels between treatments. Results Fourteen patients, 50% female, with a median age of 72 years (interquartile range [IQR], 65–77), completed the trial. Median serum sodium level at baseline was 131 mmol/L (IQR, 130–132). After treatment with empagliflozin, median serum sodium level rose to 134 mmol/L (IQR, 132–136), whereas no increase was seen with placebo (130 mmol/L; IQR, 128–132), corresponding to a serum sodium increase of 4.1 mmol/L (95% confidence interval [CI], 1.7 to 6.5; P =0.004). Exploratory analyses showed that treatment with empagliflozin led to improved neurocognitive function with an increase of 1.16 (95% CI, 0.05 to 2.26) in the MoCA score. Treatment was well tolerated; no serious adverse events were reported. Conclusion The SGLT2 inhibitor empagliflozin is a promising new treatment option for chronic SIAD-induced hyponatremia, possibly improving neurocognitive function. Larger studies are needed to confirm the observed treatment effects. Clinical Trial registration number: ClinicalTrials.gov NCT03202667." @default.
• W4309182708 created "2022-11-24" @default.
• W4309182708 creator A5016702558 @default.
• W4309182708 creator A5023489395 @default.
• W4309182708 creator A5023967301 @default.
• W4309182708 creator A5026963413 @default.
• W4309182708 creator A5028779698 @default.
• W4309182708 creator A5035475469 @default.
• W4309182708 creator A5045826714 @default.
• W4309182708 creator A5056138475 @default.
• W4309182708 creator A5057598527 @default.
• W4309182708 creator A5060720367 @default.
• W4309182708 creator A5075635162 @default.
• W4309182708 creator A5089775630 @default.
• W4309182708 date "2022-11-17" @default.
• W4309182708 modified "2023-10-16" @default.
• W4309182708 title "Treatment Effect of the SGLT2 Inhibitor Empagliflozin on Chronic Syndrome of Inappropriate Antidiuresis: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial" @default.
• W4309182708 cites W1622713230 @default.
• W4309182708 cites W1885676552 @default.
• W4309182708 cites W1976053112 @default.
• W4309182708 cites W1988476274 @default.
• W4309182708 cites W1990166011 @default.
• W4309182708 cites W1992145761 @default.
• W4309182708 cites W2003763267 @default.
• W4309182708 cites W2013173881 @default.
• W4309182708 cites W2037760360 @default.
• W4309182708 cites W2057390143 @default.
• W4309182708 cites W2111111770 @default.
• W4309182708 cites W2112224267 @default.
• W4309182708 cites W2120040647 @default.
• W4309182708 cites W2139140962 @default.
• W4309182708 cites W2146264128 @default.
• W4309182708 cites W2163726024 @default.
• W4309182708 cites W2165758561 @default.
• W4309182708 cites W2171788418 @default.
• W4309182708 cites W2202976714 @default.
• W4309182708 cites W2214942826 @default.
• W4309182708 cites W2263340295 @default.
• W4309182708 cites W2278766882 @default.
• W4309182708 cites W2293450148 @default.
• W4309182708 cites W2395683376 @default.
• W4309182708 cites W2424539745 @default.
• W4309182708 cites W2485191622 @default.
• W4309182708 cites W2775837053 @default.
• W4309182708 cites W2788315630 @default.
• W4309182708 cites W2788363286 @default.
• W4309182708 cites W2889201949 @default.
• W4309182708 cites W2905845365 @default.
• W4309182708 cites W2908754148 @default.
• W4309182708 cites W2921278352 @default.
• W4309182708 cites W2939222610 @default.
• W4309182708 cites W2971290652 @default.
• W4309182708 cites W3004975983 @default.
• W4309182708 cites W3010160114 @default.
• W4309182708 cites W3010954657 @default.
• W4309182708 cites W3081921599 @default.
• W4309182708 cites W3083520946 @default.
• W4309182708 cites W3088173406 @default.
• W4309182708 cites W3099091911 @default.
• W4309182708 cites W3193370765 @default.
• W4309182708 cites W3195883812 @default.
• W4309182708 cites W4283021686 @default.
• W4309182708 cites W4294554863 @default.
• W4309182708 doi "https://doi.org/10.1681/asn.2022050623" @default.
• W4309182708 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36396331" @default.
• W4309182708 hasPublicationYear "2022" @default.
• W4309182708 type Work @default.
• W4309182708 citedByCount "15" @default.
• W4309182708 countsByYear W43091827082022 @default.
• W4309182708 countsByYear W43091827082023 @default.
• W4309182708 crossrefType "journal-article" @default.
• W4309182708 hasAuthorship W4309182708A5016702558 @default.
• W4309182708 hasAuthorship W4309182708A5023489395 @default.
• W4309182708 hasAuthorship W4309182708A5023967301 @default.
• W4309182708 hasAuthorship W4309182708A5026963413 @default.
• W4309182708 hasAuthorship W4309182708A5028779698 @default.
• W4309182708 hasAuthorship W4309182708A5035475469 @default.
• W4309182708 hasAuthorship W4309182708A5045826714 @default.
• W4309182708 hasAuthorship W4309182708A5056138475 @default.
• W4309182708 hasAuthorship W4309182708A5057598527 @default.
• W4309182708 hasAuthorship W4309182708A5060720367 @default.
• W4309182708 hasAuthorship W4309182708A5075635162 @default.
• W4309182708 hasAuthorship W4309182708A5089775630 @default.
• W4309182708 hasConcept C126322002 @default.
• W4309182708 hasConcept C126894567 @default.
• W4309182708 hasConcept C134018914 @default.
• W4309182708 hasConcept C142724271 @default.
• W4309182708 hasConcept C159641895 @default.
• W4309182708 hasConcept C168563851 @default.
• W4309182708 hasConcept C204787440 @default.
• W4309182708 hasConcept C27081682 @default.
• W4309182708 hasConcept C2775887513 @default.
• W4309182708 hasConcept C2776703092 @default.
• W4309182708 hasConcept C2777180221 @default.
• W4309182708 hasConcept C33893070 @default.
• W4309182708 hasConcept C555293320 @default.
• W4309182708 hasConcept C71924100 @default.
• W4309182708 hasConcept C87813604 @default.

• next